Microbiology, antibiotic susceptibility, and bacteraemia associated factors in acute prostatitis

Introduction: The aim of the study was to analyze the characteristics of patients with acute prostatitis presenting to the Emergency Department, the microbiological findings, antibiotic susceptibility, and bacteraemia associated factors. Methods. Observational and cohort study with prospective follow-up including patients with acute prostatitis presenting to the Emergency Department from January-December 2012. Data were collected for demographic variables, comorbidities, microbiological findings, antibiotic treatment and outcome. Results: Two hundred and forty one episodes of acute prostatitis were included. Mean age was 62.9 ± 16 years, a history of prostate adenoma was reported in 54 cases (22.5%) and prior manipulation of the lower urinary tract in 40 (17%). Mean symptoms duration was 3.38 ± 4.04 days, voiding symptoms were present in 176 cases (73%) and fever in 154 (64%). Seventy patients (29%) were admitted to the hospital and 3 died. From 216 urine cultures, 128 were positive (59%) and 24 (17.6%) out of 136 blood cultures. Escherichia coli was the main pathogen (58.6% of urine cultures and 64% of blood cultures) with resistant strains to fluoroquinolones, cotrimoxazole and amoxicillin/clavulanic in 27.7%, 22.9% and 27.7% of cases respectively. In the univariate analysis, only chills were associated to bacteraemia (p=0.013). At 30-day follow-up, patients with bacteraemia returned more frequently to the Emergency Department (p=0.037) and were more often admitted to the hospital (p=0.003). Conclusions: Patients with acute prostatitis discharged from the Emergency Department need clinical follow-up and monitoring of microbiological findings in order to assure an adequate antibiotic treatment. Return to Emergency Department and admission to the hospital were significantly more frequent among patients with bacteraemia

Disnea por distonía de hipofaringe inducida por metoclopramida: una emergencia a tener en cuenta

La distonía laríngea es una emergencia infradiagnosticada, que puede constituir una emergencia vital.Paciente de 25 años sin antecedentes patológicos de interés que consultó por disnea aguda, sin otra clínica acompañante. A su llegada a urgencias estaba hemodinámicamente estable, con una saturación de oxígeno del 100% respirando aire ambiente, una auscultación respiratoria con murmullo vesicular conservado y con ruidos (ronquidos) a nivel laríngeo

The effect of simvastatin on inflammatory cytokines in community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial

Objectives: it has been suggested that statins have an effect on the modulation of the cytokine cascade and on the outcome of patients with community-acquired pneumonia (CAP). The aim of this prospective, randomised, double-blind, placebo-controlled trial was to determine whether statin therapy given to hospitalised patients with CAP improves clinical outcomes and reduces the concentration of inflammatory cytokines. Setting: a tertiary teaching hospital in Barcelona. Participants: thirty-four patients were randomly assigned and included in an intention-to-treat analysis (19 to the simvastatin group and 15 to the placebo group). Intervention: patients were randomly assigned to receive 20 mg of simvastatin or placebo administered in the first 24 h of hospital admission and once daily thereafter for 4 days. Outcome: primary end point was the time from hospital admission to clinical stability. The secondary end points were serum concentrations of inflammatory cytokines and partial pressure of arterial oxygen/fractional inspired oxygen (PaO2/FiO2) at 48 h after treatment administration. Results: the trial was stopped because enrolment was much slower than originally anticipated. The baseline characteristics of the patients and cytokine concentrations at the time of enrolment were similar in the two groups. No significant differences in the time from hospital admission to clinical stability were found between study groups (median 3 days, IQR 2-5 vs 3 days, IQR 2-5; p=0.47). No significant differences in PaO2/FiO2 (p=0.37), C reactive protein (p=0.23), tumour necrosis factor-α (p=0.58), interleukin 6 (IL-6; p=0.64), and IL-10 (p=0.61) levels at 48 h of hospitalisation were found between simvastatin and placebo groups. Similarly, transaminase and total creatine kinase levels were similar between study groups at 48 h of hospitalisation (p=0.19, 0.08 and 0.53, respectively). Conclusions: our results suggest that the use of simvastatin, 20 mg once daily for 4 days, since hospital admission did not reduce the time to clinical stability and the levels of inflammatory cytokines in hospitalised patients with CAP

Evaluación de la uitilidad de la tinción de Gram del esputo para el manejo de la neumonía en urgencias

Objetivo: Evaluar la utilidad de la tinción de Gram del esputo (TGE) en el manejo de la neumonía adquirida en la comunidad (NAC) en el servicio de urgencias (SU). Método: Estudio descriptivo y retrospectivo entre octubre 2005 y noviembre 2007 de pacientes con NAC ingresados en el hospital tras su valoración en el SU. Se han analizado las variables demográficas, índice de Fine, TGE, antigenuria, cultivos y antibioterapia inicial. Se ha calculado la sensibilidad, la especificidad y los valores predictivos positivo y negativo de la TGE. Resultados: Se ha revisado 608 casos de neumonía (edad media 70,7, 64,3% hombres). Se obtuvo muestras de esputo en 168 pacientes (27,6%). La TGE mostró diplococos Gram positivos en 74 casos (DCGP), cocobacilos Gram negativos (CBGN) en 26, bacilos Gram negativos en 15, cocos Gram positivos en racimo o cadenas en 11 y presencia de polimorfonucleares sin predominio de microorganismos en 42. Se aisló Streptococcus pneumoniae en 57 casos y Haemophilus influenzae en 19. El hallazgo de DCGP o CBGN mostró una sensibilidad del 47,1% y 73% y una especificidad del 94,2% y 95% para la infección neumocócica y por Haemophilus respectivamente. Ceftriaxona fue el tratamiento más frecuente en pacientes con DGCP y levofloxacino en CBGN. Conclusiones: La TGE tiene un valor limitado en el manejo de la NAC del adulto en el SU con resultados variables según la infecciones por lo que resulta poco útil para orientar la antibioterapia inicial

Frequency of five cardiovascular/hemostatic entities as primary manifestations of SARS-CoV-2 infection: Results of the UMC-19-S2

Infection by SARS-Cov-2 is mainly characterized by fever and respiratory symptoms, with dyspnea and lung infiltrates in more severe cases [1,2]. Many patients also present a pro-coagulant state, which is biochemically detected by increased D-dimer levels and is related to complications and a worse prognosis [1,3]. In this context, isolated case reports and short case series have suggested an increased risk of patients with COVID-19 to develop clinically relevant cardiovascular and hemostatic disturbances [3–7]. Nonetheless, many of these reports refer to hospitalized patients, and as hospitalization itself usually increases complications in bedridden patients with multidrug treatmentor in very poor condition, it is unknown if such cardiovascular/hemostatic processes are related to the pathogenesis of SARS-Cov-2. Focus on patients with COVID-19 at emergency department (ED) arrival could help to answer this question

Análisis de los resultados de gestión de las unidades de corta estancia españolas según su dependencia funcional

Objetivo. Comparar los resultados de gestión clínica de las unidades de corta estancia (UCE) según su dependencia funcional. Metodología. Estudio de análisis transversal realizado en 40 hospitales con UCE (1 junio-31 diciembre 2012). Se recogieron datos de actividad y gestión clínica, considerando como variables directamente relacionadas con la eficiencia la estancia media, el índice de rotación por cama y el porcentaje de altas en fin de semana. Resultados. Se analizaron 40 UCE, 25 (62,5%) dependientes del servicio de urgencias (UCEU), 9 (22,5%) de medicina interna (UCEMI), 5 (12,5%) independientes (UCEI) y 1 con dependencia mixta (UCEU + UCEMI). El número total de altas fue de 45.140. Los diagnósticos más frecuentes fueron la exacerbación de la patología crónica cardiaca y respiratoria, la infección urinaria y la respiratoria. En relación a su dependencia funcional no se observaron diferencias en los parámetros analizados intergrupos salvo en la edad media (UCEI 75,6 años vs UCEU 67,2 vs UCEMI 57,8; p = 0,02). Al realizar la comparación intragrupos, la estancia media fue menor en las UCEU que las UCEMI (2,65 días vs 3,73; p = 0,047) y la mortalidad global menor en las UCEMI que las UCEU (0,64% vs 3%; p = 0,033), pero sin diferencias al comparar la mortalidad no esperada una vez excluidos los pacientes paliativos y/o en situación de últimas horas. Conclusión. En la serie analizada no se observan diferencias destacables al comparar las UCE en conjunto según dependencia funcional. Sin embargo, en el análisis intragrupos las UCEU lograron menor estancia media que las UCEMI

Community-acquired pneumonia management in a short-stay unit: analysis of safety and efficacy

Podeu consultar la versió en castellà a: http://hdl.handle.net/2445/119397Background and objective: Community-acquired pneumonia (CAP) is a highly prevalent disease that often requires hospital admission. We aimed to assess the safety and efficacy of treating CAP in a short-stay unit as an alternative to conventional hospitalization. Methods: Retrospective comparison of patients admitted to a tertiary care hospital with a diagnosis of CAP between November 2005 and April 2007. We compared outcomes for cases managed in the 2 locations (short-stay unit vs conventional hospital ward), excluding patients who required intensive care. Variables and outcomes analyzed were age, sex, Charlson index, mean weight in the diagnosis-related group, scores on the CURB-65 criteria and the Pneumonia Severity Index (PSI), findings of microbiology, and readmission and mortality rates. Results: A total of 606 patients were studied; 187 were treated in the short-stay unit and 419 were admitted to the conventional ward. The main significant differences between the 2 groups were mean age (77.3 vs 67.9 years, respectively; P<.0001) and mean stay (3.48 vs 7.89 days; P<.0001). These differences were also reflected in the comparison between severity subgroups (by PSI). Mortality rates did not differ. Conclusions: Our experience with the short-stay unit suggests it offers a safe and effective way to manage CAP and leads to a significantly shorter hospital stay in comparison with conventional hospitalization, without increasing readmission and mortality rates

Análisis de la seguridad y la eficacia de una unidad de corta estancia en el tratamiento de la neumonía adquirida en la comunidad

Podeu consultar la versió en anglès a: http://hdl.handle.net/2445/119414Introducción: La neumonía adquirida en la comunidad (NAC) es una patología de alta prevalencia que a menudo requiere ingreso hospitalario. El objetivo de nuestro estudio es evaluar la eficacia y seguridad en el tratamiento de la NAC de una unidad de corta estancia (UCE) como alternativa a las unidades de hospitalización convencional (UHC). Método: Estudio retrospectivo comparativo de pacientes ingresados en un hospital terciario con diagnóstico al alta de NAC entre noviembre del 2005 y abril del 2007. Se comparan dos grupos: pacientes ingresados en UCE frente a pacientes ingresados en UHC (se excluyen pacientes que requieren terapia intensiva). Variables analizadas: edad y sexo, índice de Charlson, peso según el grupo relacionado de diagnóstico (GRD), CURB 65 y Pneumonia Severity Index (PSI), hallazgos microbiológicos, tasas de readmisión y de mortalidad. Resultados: Un total de 606 pacientes fueron reclutados, 187 ingresados en el UCE (grupo 1) y 419 en UHC (grupo 2 o grupo control). Las diferencias más significativas entre los dos grupos fueron el promedio de edad (77,3 vs 67,9 p < 0,001) y la estancia promedio (3,48 vs 7,89 p < 0,001). Estas diferencias se objetivan en el comparativo general y por subgrupos según la escala de riesgo (PSI). No se observaron diferencias significativas en la tasa de mortalidad ni en la de reingreso entre las dos formas de hospitalización. Conclusiones: La UCE es eficaz y segura en el manejo de los pacientes con NAC, con una estancia media significativamente inferior respecto a las UHC, y sin diferencias en las tasas de mortalidad y reingreso

A multicenter, open-label, randomized, proof-of-concept phase II clinical trial to assess the efficacy and safety of icatibant in patients infected with SARS-CoV-2 (COVID-19) and admitted to hospital units without invasive mechanical ventilation: study protocol (ICAT-COVID)

Background: COVID-19 has quickly become a global pandemic with a substantial number of deaths and is a considerable burden for healthcare systems worldwide. Although most cases are paucisymptomatic and limited to the viral infection-related symptoms, some patients evolve to a second phase, with an impaired inflammatory response (cytokine storm) that may lead to acute respiratory distress syndrome and death. This is thought to be caused by increased bradykinin synthesis. Methods: ICAT-COVID is a multicenter, randomized, open-label, proof-of-concept phase II clinical trial assessing the clinical efficacy and safety of adding icatibant to the standard of care in patients hospitalized with COVID-19 without invasive mechanical ventilation. Patients hospitalized with a confirmed COVID-19 pneumonia diagnosis (RTPCR or antigen test <= 10 days prior to randomization, and radiographic evidence of pulmonary infiltrates), rated 4 or 5' on the WHO's clinical status scale, are eligible. Patients will be randomized on a 1:1 ratio to either standard of care-plus-icatibant (experimental group) or to standard of care alone (control group). The experimental group will receive 30 mg of icatibant subcutaneously 3 times a day for 3 days (for a total of 9 doses). The expected sample size is 120 patients (60 per group) from 2 sites in Spain. Primary outcomes are the efficacy and safety of Icatibant. The main efficacy outcome is the number of patients reaching grades 2 or 1 on the WHO scale within 10 days of starting treatment. Secondary outcomes include long-term efficacy: number of patients discharged who do not present COVID-19-related relapse or comorbidity up until 28 days after discharge, and mortality. Discussion: Icatibant, a bradykinin type 2 receptor antagonist with proven effectiveness and safety against hereditary angioedema attacks, may be beneficial for COVID-19 patients by inhibiting bradykinin's action on endothelial cells and by inhibiting the SARS-CoV-2 M protease. Our working hypothesis is that treatment with standard of care-plus-icatibant is effective and safe to treat patients infected with SARS-CoV-2 admitted to hospital for pneumonia without invasive mechanical ventilation

Incidence, clinical characteristics, risk factors and outcomes of meningoencephalitis in patients with COVID-19

We investigated the incidence, clinical characteristics, risk factors, and outcome of meningoencephalitis (ME) in patients with COVID-19 attending emergency departments (ED), before hospitalization. We retrospectively reviewed all COVID patients diagnosed with ME in 61 Spanish EDs (20% of Spanish EDs, COVID-ME) during the COVID pandemic. We formed two control groups: non-COVID patients with ME (non-COVID-ME) and COVID patients without ME (COVID-non-ME). Unadjusted comparisons between cases and controls were performed regarding 57 baseline and clinical characteristics and 4 outcomes. Cerebrospinal fluid (CSF) biochemical and serologic findings of COVID-ME and non-COVID-ME were also investigated. We identified 29 ME in 71,904 patients with COVID-19 attending EDs (0.40‰, 95%CI=0.27-0.58). This incidence was higher than that observed in non-COVID patients (150/1,358,134, 0.11‰, 95%CI=0.09-0.13; OR=3.65, 95%CI=2.45-5.44). With respect to non-COVID-ME, COVID-ME more frequently had dyspnea and chest X-ray abnormalities, and neck stiffness was less frequent (OR=0.3, 95%CI=0.1-0.9). In 69.0% of COVID-ME, CSF cells were predominantly lymphocytes, and SARS-CoV-2 antigen was detected by RT-PCR in 1 patient. The clinical characteristics associated with a higher risk of presenting ME in COVID patients were vomiting (OR=3.7, 95%CI=1.4-10.2), headache (OR=24.7, 95%CI=10.2-60.1), and altered mental status (OR=12.9, 95%CI=6.6-25.0). COVID-ME patients had a higher in-hospital mortality than non-COVID-ME patients (OR=2.26; 95%CI=1.04-4.48), and a higher need for hospitalization (OR=8.02; 95%CI=1.19-66.7) and intensive care admission (OR=5.89; 95%CI=3.12-11.14) than COVID-non-ME patients. ME is an unusual form of COVID presentation (<0.5‰ cases), but is more than 4-fold more frequent than in non-COVID patients attending the ED. As the majority of these MEs had lymphocytic predominance and in one patient SARS-CoV-2 antigen was detected in CSF, SARS-CoV-2 could be the cause of most of the cases observed. COVID-ME patients had a higher unadjusted in-hospital mortality than non-COVID-ME patients